TY - JOUR
T1 - Assessment of a revolving drug fund for essential asthma medicines in Benin
AU - Agodokpessi, Gildas
AU - Aït-Khaled, Nadia
AU - Gninafon, Martin
AU - Tawo, Leon
AU - Bekou, Wilfried
AU - Perrin, Christophe
AU - Bissell, Karen
AU - Billo, Nils
AU - Enarson, Donald A.
AU - Chiang, Chen Yuan
N1 - Publisher Copyright:
© 2015 Morrow; licensee BioMed Central.
PY - 2015
Y1 - 2015
N2 - Objectives: Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. Methods: We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013. Results: The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013. Conclusion: The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.
AB - Objectives: Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. Methods: We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013. Results: The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013. Conclusion: The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.
KW - Asthma
KW - Beclometasone
KW - Inhaled corticosteroid
KW - Revolving drug fund
UR - http://www.scopus.com/inward/record.url?scp=84983161313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983161313&partnerID=8YFLogxK
U2 - 10.1186/s40545-015-0033-7
DO - 10.1186/s40545-015-0033-7
M3 - Article
AN - SCOPUS:84983161313
SN - 2052-3211
VL - 8
SP - 1
EP - 8
JO - Journal of Pharmaceutical Policy and Practice
JF - Journal of Pharmaceutical Policy and Practice
IS - 1
M1 - 12
ER -
